Lifecore Biomedical to be Added to Nasdaq Biotech Index

Lifecore Biomedical, Inc. (NASDAQ: LFCR), a prominent contract development and manufacturing organization (CDMO), is set to be added to the Nasdaq Biotech Index on December 22, 2025. This addition, announced on December 18, 2025, highlights Lifecore's growing profile within the biopharmaceutical sector. The Nasdaq Biotech Index consists of Nasdaq-listed companies engaged in biotechnology and pharmaceutical activities, utilizing a modified capitalization-weighted index methodology to track their performance.

Lifecore specializes in the development and manufacturing of sterile injectable pharmaceutical products, including those in syringes, vials, and cartridges. The company is renowned for its expertise in producing high-quality injectable-grade hyaluronic acid, positioning itself as a key partner for both established and emerging biopharmaceutical companies across various therapeutic areas. With over 40 years of industry experience, Lifecore's capabilities include the development of complex formulations, tapping into a range of therapeutic categories to support innovation in drug development.

The company's inclusion in the Nasdaq Biotech Index is a significant milestone, reflecting its adherence to stringent eligibility criteria set by Nasdaq, which includes market capitalization, trading volume, and a proven record as a public company. This recognition not only solidifies Lifecore's standing in the biotechnology field but also enhances its visibility among investors and stakeholders, showcasing its commitment to supporting the advancement of medical therapies.

For further information about Lifecore Biomedical and its services, interested parties can visit the company's website at www.lifecore.com or contact the appropriate representatives listed in their official communications.

Lifecore Biomedical (NASDAQ: LFCR), a prominent contract development and manufacturing organization (CDMO), is poised to make a significant impact with its upcoming addition to the Nasdaq Biotech Index (NBI) on December 22, 2025. This inclusion is a strong affirmation of Lifecore’s operational robustness, market credibility, and growth potential, making it an intriguing opportunity for investors.

As a leader in the production of sterile injectable pharmaceutical products and a specialist in hyaluronic acid, Lifecore has cultivated over 40 years of expertise and partnerships within the biopharmaceutical sector. The company’s diverse capabilities, particularly in developing complex formulations, position it favorably against competitors and align with current trends emphasizing the need for advanced biopharmaceutical manufacturing solutions.

Inclusion in the NBI not only enhances Lifecore’s visibility among institutional investors but also taps into a growing market sentiment around biotechnology stocks, which have historically outperformed other sectors during innovation-driven market cycles. As the industry evolves with increasing demand for injectable therapies and biologics, Lifecore is well-equipped to capitalize on these trends.

Investors should closely monitor Lifecore's financial health, focusing on its revenue growth, earnings reports, and expansion initiatives, particularly as it looks to leverage its new status on the NBI. The anticipated uptick in trading volume following the inclusion could also stabilize LFCR’s share price and pave the way for broader institutional ownership.

In conclusion, with its robust positioning within the biotech landscape, Lifecore Biomedical represents a compelling investment opportunity. Stakeholders should consider entering or increasing their positions ahead of the NBI inclusion, keeping an eye on market dynamics and financial updates that may affect stock performance in the months ahead.